EUCTR2005-001294-99-IT进行中（未招募）不适用
A randomized two-by-two, multicenter, open-label phase III study of BMS-354825 administered orally at a dose of 50 mg or 70 mg twice daily or 100 mg or 140 mg once daily in subjects with chronic phase Philadelphia chromosome or BCR-ABL positive chronic myelogenous leukemia who are resistant or intolerant to imatinib mesylate (Gleevec). Revised protocol 06 incorporating administrative letters 01, 02, 03, 04 and 05 and amendments 01, 02, 03, 04 and 05 (v1.0 dated 14 Sep 2010).
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 入组人数
- 400
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Are the trial subjects under 18? no
- •Number of subjects for this age range: 0
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- 未提供
研究者
相似试验
进行中（未招募）
不适用
A Randomized Two-by-Two, Multicenter, Open-Label Phase III Study of BMS-354825 Administered Orally at a Dose of 50 mg or 70 mg Twice Daily or 100 mg or 140 mg Once Daily in Subjects with Chronic Phase Philadelphia Chromosome or BCR-ABL Positive Chronic Myelogenous Leukemia Who are Resistant or Intolerant to Imatinib Mesylate (Gleevec®)Revised Protocol 01 version 3.0, incorporating Administrative Letter 01Subjects with Chronic Phase Philadelphia Chromosome or BCR-ABL Positive Chronic Myelogenous Leukemia who are resistant or intolerant to Imatinib MesylateEUCTR2005-001294-99-EEBristol-Myers Squibb International Corporation400
进行中（未招募）
不适用
A Randomized Two-by-Two, Multicenter, Open-Label Phase III Study of BMS-354825 Administered Orally at a Dose of 50 mg or 70 mg Twice Daily or 100 mg or 140 mg Once Daily in Subjects with Chronic Phase Philadelphia Chromosome or BCR-ABL Positive Chronic Myelogenous Leukemia Who are Resistant or Intolerant to Imatinib Mesylate.Revised Protocol 06, incorporating Administrative Letters 01, 02, 03, 04 and 05 and Amendments 01, 02, 03, 04 and 05 (v1.0, dated 14-Sep-2010)EUCTR2005-001294-99-DKBristol-Myers Squibb International Corporation400
进行中（未招募）
不适用
A Randomized Two-by-Two, Multicenter, Open-Label Phase III Study of BMS-354825 Administered Orally at a Dose of 50 mg or 70 mg Twice Daily or 100 mg or 140 mg Once Daily in Subjects with Chronic Phase Philadelphia Chromosome or BCR-ABL Positive Chronic Myelogenous Leukemia Who are Resistant or Intolerant to Imatinib Mesylate.Revised Protocol 05, incorporating Administrative Letters 01, 02, 03 and 04 and Amendments 01, 02, 03 (v1.0, dated 28-Feb-2008) and 04 (v1.0, dated 19-Dec-2008)EUCTR2005-001294-99-ATBristol-Myers Squibb International Corporation400
进行中（未招募）
不适用
A Randomized Two-by-Two, Multicenter, Open-Label Phase III Study of BMS-354825 Administered Orally at a Dose of 50 mg or 70 mg Twice Daily or 100 mg or 140 mg Once Daily in Subjects with Chronic Phase Philadelphia Chromosome or BCR-ABL Positive Chronic Myelogenous Leukemia Who are Resistant or Intolerant to Imatinib Mesylate.Revised Protocol 06, incorporating Administrative Letters 01, 02, 03, 04 and 05 and Amendments 01, 02, 03, 04 and 05 (v1.0, dated 14-Sep-2010)Subjects with Chronic Phase Philadelphia Chromosome or BCR-ABL Positive Chronic Myelogenous Leukemia who are resistant or intolerant to Imatinib MesylateEUCTR2005-001294-99-CZBristol-Myers Squibb International Corporation400
进行中（未招募）
不适用
Chronic Myelogenous Leukemia (CML) - Follow-up: Study BMS354825 in Subjects with CMSubjects with Chronic Phase Philadelphia Chromosome or BCR-ABL Positive Chronic Myelogenous Leukemia who are resistant or intolerant to Imatinib MesylateMedDRA version: 14.1Level: LLTClassification code 10009700Term: CMLSystem Organ Class: 100000004864EUCTR2005-001294-99-BEBristol-Myers Squibb International Corporation400